Small Molecule Anticancer Drug Development Services

Small molecule anticancer drugs have evolved from an 'empirical therapies' approach to a sophisticated modality that can alter specific cellular functions. Protheragen is well known for providing full service in small molecule anticancer drug development and further offers a unique blend of creativity, experience, and effectiveness in dealing with clients' needs.

Overview of Small Molecule Anticancer Drug

Anticancer drugs that qualify as small molecules disrupt the cellular processes of cancer cells through modulation of intracellular proteins, DNA, and enzyme systems within the cells. Such chemical compounds possess a molecular weight less than 1,000 Da, granting them the ability to be administered orally, have high bioavailability, and penetrate tissues easily. Small molecules differ from biologics in that their oncology therapeutic mechanisms provide targeted approaches through interactions with precise pathways.

Fig.1 Discovery and development from gene to drug. (Jenča A., et al., 2024)

They include, among others, inhibitors of tyrosine kinases, proteasomes, topoisomerases, as well as histone deacetylases and more. Oncogenic signal transduction, cell cycle checkpoint maintenance, and apoptosis or autophagy induction in malignant cells can be achieved via small molecule binding to ATP-binding sites or allosteric sites on proteins. Small molecules' modular chemical structures make them easier to refine in pharmacokinetics and safety profiles during medicinal chemistry processes.

Development of Small Molecule Anticancer Drug

Small-molecule drugs represent the cornerstone of targeted cancer therapy. The molecular etiology of many cancers—such as EGFR mutations in non-small cell lung cancer, BCR-ABL translocations in chronic myeloid leukemia, and FLT3-ITD mutations in acute myeloid leukemia—has guided the rational design of small molecule inhibitors that selectively block these driving abnormalities.

Examples include:

• EGFR Inhibitors (e.g., gefitinib, osimertinib): selectively target mutant EGFR, improving survival in NSCLC patients with T790M mutations.
• ALK Inhibitors (e.g., crizotinib, lorlatinib): suppress ALK fusion-driven tumors and overcome CNS metastasis through BBB penetration.
• FLT3 Inhibitors (e.g., gilteritinib): address both ITD and TKD variants of FLT3 mutations in AML.

Small molecules are also integral in overcoming treatment resistance. Third-generation inhibitors are developed specifically to counteract mutations that evade first- and second-generation drugs. Moreover, combination regimens with immune checkpoint inhibitors or anti-angiogenic agents have shown synergistic effects in tumors with heterogeneous microenvironments.

Table 1. Timeline for the approval of small-molecule targeted anti-cancer drugs. (Zhong L., et al., 2021)

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Protheragen's integrated service model is designed for biotechnology firms, academic researchers, and pharmaceutical companies seeking reliable, scalable solutions in oncology R & D. We specialize in both first-in-class and best-in-class candidate development, with extensive capabilities in kinase inhibitors, epigenetic modulators, and autophagy inducers.

Workflow of Small Molecule Anticancer Drug Development

Target Identification and Validation

We employ CRISPR screening, transcriptomics, and AI-integrated pathway analysis to pinpoint and validate oncogenic drivers and resistance nodes.

Hit Discovery and High-Throughput Screening (HTS)

Leveraging compound libraries exceeding 1 million structures, we use cell-based and biochemical assays to rapidly identify hits with desirable potency and selectivity.

Lead Optimization and Medicinal Chemistry

Through iterative SAR (structure-activity relationship) analysis, we optimize leads for:

• Enhanced binding affinity
• Metabolic stability
• Favorable ADME profiles
• Minimal cytotoxicity

In Vitro and In Vivo Studies

We perform comprehensive pharmacodynamic, pharmacokinetic and drug safety studies, supported by:

• Xenograft and orthotopic models
• Tumor organoids
• PDX (patient-derived xenograft) platforms

Types of Small Molecule Anticancer Drug Development

• Alkylating Antineoplastic Agent
• Antibiotics
• Platinum-based Drug
• Antimetabolites

• Topoisomerase Inhibitor
• Genotoxic Drug
• Spindle Inhibitor
• Spindle Inhibitor

Our Analytics Platform

Protheragen stands at the forefront of innovation in small-molecule anticancer drug development. With unmatched scientific depth, agile project execution, and an unwavering commitment to precision oncology, we empower our partners to turn bold ideas into clinical realities. If you are interested in our services, please feel free to contact us.

References

• Ma, Yu-Shui, et al. "Basic approaches, challenges and opportunities for the discovery of small molecule anti-tumor drugs." American Journal of Cancer Research 11.6 (2021): 2386.
• Zhong, Lei, et al. "Small molecules in targeted cancer therapy: advances, challenges, and future perspectives." Signal transduction and targeted therapy 6.1 (2021): 201.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.